Iovance Biotherapeutics (NASDAQ:IOVA) announces that the last patient has completed dosing in cohort 4 of its Phase 2 registration-enabling study, C-144-01, evaluating cell therapy lifileucel (LN-144) in metastatic melanoma patients, a Fast Track, Regenerative Medicine Advanced Therapy and Orphan Drug indication.
The primary endpoint of the 164-subject trial is objective response rate (ORR) up to month 54 (every six weeks for six months, then every three months thereafter).
The company says it remains on track to file a U.S. marketing application in Q4.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.